• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by IGM Biosciences Inc.

    8/2/24 6:41:27 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IGMS alert in real time by email
    SC 13G/A 1 d820351dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934*

    (Amendment No. 4)

     

     

    IGM Biosciences, Inc.

    (Name of Issuer)

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

    449585108

    (CUSIP Number)

    July 25, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 449585108   13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Invus Public Equities, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Bermuda

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     3,330,422

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     3,330,422

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,330,422

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    2


    CUSIP No. 449585108   13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Invus Public Equities Advisors, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     3,330,422

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     3,330,422

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,330,422

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    3


    CUSIP No. 449585108   13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Invus Global Management, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     3,330,422

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     3,330,422

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,330,422

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    4


    CUSIP No. 449585108   13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Siren, L.L.C.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     3,330,422

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     3,330,422

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,330,422

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    5


    CUSIP No. 449585108   13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Raymond Debbane

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Panama

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     3,330,422

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     3,330,422

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,330,422

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    6


    CUSIP No. 449585108   13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal International S.C.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    7


    CUSIP No. 449585108   13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal International Management S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    8


    CUSIP No. 449585108   13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal Group S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    9


    CUSIP No. 449585108   13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Westend S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    10


    CUSIP No. 449585108   13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Stichting Administratiekantoor Westend

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    11


    CUSIP No. 449585108   13G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Mr. Amaury Wittouck

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Belgium

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    12


    Explanatory Note

    On July 25, 2024, in connection with a reorganization (the “Reorganization”), Global Management replaced the Geneva branch of Artal International as the managing member of Invus PE Advisors (each defined below). Siren (defined below) is the managing member of Global Management and Mr. Raymond Debbane is the managing member of Siren. Accordingly, Artal International, Artal International Management, Artal Group, Westend, the Stichting and Mr. Amaury Wittouck (each defined below and together, the “Artal Parties”) are no longer deemed to beneficially own the Shares directly held by Invus Public Equities (defined below). This Schedule 13G reports beneficial ownership as of July 25, 2024, immediately following the Reorganization, and reflects an exit filing by the Artal Parties and an initial filing on Schedule 13G by Global Management, Siren and Mr. Debbane. See Item 4.

     

    Item 1(a).

    Name of Issuer:

    IGM Biosciences, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    325 E. Middlefield Road, Mountain View, CA 94043

     

    Item 2(a).

    Name of Person Filing:

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

     

    Item 2(c).

    Citizenship:

    (i) Invus Public Equities, L.P. (“Invus Public Equities”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Bermuda limited partnership

    (ii) Invus Public Equities Advisors, LLC (“Invus PE Advisors”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Delaware limited liability company

    (iii) Invus Global Management, LLC (“Global Management”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Delaware limited liability company

    (iv) Siren, L.L.C. (“Siren”)

    c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Delaware limited liability company

    (v) Raymond Debbane

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Panama

    (vi) Artal International S.C.A. (“Artal International”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg limited partnership

    (vii) Artal International Management S.A. (“Artal International Management”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (viii) Artal Group S.A. (“Artal Group”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (ix) Westend S.A. (“Westend”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

     

    13


    (x) Stichting Administratiekantoor Westend (the “Stichting”)

    Claude Debussylaan, 46, 1082 MD Amsterdam, The Netherlands

    Citizenship: Netherlands foundation

    (xi) Mr. Amaury Wittouck

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Belgium

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.01 per share (the “Shares”)

     

    Item 2(e).

    CUSIP Number:

    449585108

     

    Item 3.

    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

    This Item 3 is not applicable.

     

    Item 4.

    Ownership.

    (a) Amount beneficially owned:

    As of July 25, 2024, following the Reorganization whereby Global Management became the managing member of Invus PE Advisors, Invus Public Equities directly held 3,330,422 Shares. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares directly held by Invus Public Equities. Global Management, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Siren, as the managing member of Global Management, controls Global Management and, accordingly, may be deemed to beneficially own the Shares that Global Management may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren, controls Siren and, accordingly, may be deemed to beneficially own the Shares that Siren may be deemed to beneficially own.

    (b) Percent of class:

    As of July 25, 2024, following the Reorganization, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person’s cover page. Calculations of the percentage of Shares beneficially owned are based on 33,636,592 Shares outstanding as of May 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2024.

    (c) Number of shares as to which Invus Public Equities, Invus PE Advisors, Global Management, Siren and Mr. Debbane has:

     

      (i)

    Sole power to vote or to direct the vote:

    3,330,422

     

      (ii)

    Shared power to vote or to direct the vote:

    0

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    3,330,422

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    0

     

    14


    As of July 25, 2024, following the Reorganization, Artal International, Artal International Management, Artal Group, Westend, the Stichting and Mr. Wittouck are no longer deemed to beneficially own any Shares.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    On July 25, 2024, in connection with the Reorganization, Global Management replaced the Geneva branch of Artal International as the managing member of Invus PE Advisors. Accordingly, the Geneva branch of Artal International, Artal International Management, Artal Group, Westend, Stichting and Mr. Wittouck are no longer deemed to beneficially own the Shares directly held by Invus Public Equities and have ceased to be Reporting Persons.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    This Item 6 is not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    This Item 7 is not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    This Item 8 is not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    This Item 9 is not applicable.

     

    Item 10.

    Certification.

    Each of the Reporting Persons hereby makes the following certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    15


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: August 2, 2024

     

    INVUS PUBLIC EQUITIES, L.P.
    By:   INVUS PUBLIC EQUITIES ADVISORS, LLC, its general partner
    By:  

    /s/ Raymond Debbane

    Name:   Raymond Debbane
    Title:   President
    INVUS PUBLIC EQUITIES ADVISORS, LLC
    By:  

    /s/ Raymond Debbane

    Name:   Raymond Debbane
    Title:   President
    INVUS GLOBAL MANAGEMENT, LLC
    By:  

    /s/ Raymond Debbane

    Name:   Raymond Debbane
    Title:   President
    SIREN, L.L.C.
    By:  

    /s/ Raymond Debbane

    Name:   Raymond Debbane
    Title:   President
    MR. RAYMOND DEBBANE
    By:  

    /s/ Raymond Debbane

    ARTAL INTERNATIONAL S.C.A.
    By:   ARTAL INTERNATIONAL MANAGEMENT S.A., its managing partner
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Managing Director


    ARTAL INTERNATIONAL MANAGEMENT S.A.
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Managing Director
    ARTAL GROUP S.A.
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Authorized Person
    WESTEND S.A.
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Managing Director
    STICHTING ADMINISTRATIEKANTOOR WESTEND
    By:  

    /s/ Amaury Wittouck

    Name:   Amaury Wittouck
    Title:   Sole Member of the Board
    MR. AMAURY WITTOUCK
    By:  

    /s/ Amaury Wittouck


    EXHIBIT INDEX

     

    Exhibit
    Number

      

    Title

    1.    Joint Filing Agreement

     

    Get the next $IGMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IGMS

    DatePrice TargetRatingAnalyst
    1/10/2025$21.00 → $2.00Outperform → Market Perform
    BMO Capital Markets
    1/10/2025$12.00 → $2.00Equal-Weight → Underweight
    Morgan Stanley
    1/10/2025$27.00 → $2.50Buy → Hold
    Stifel
    1/10/2025$20.00 → $1.50Outperform → Sector Perform
    RBC Capital Mkts
    1/10/2025Buy → Neutral
    Guggenheim
    12/6/2024$21.00Outperform
    BMO Capital Markets
    10/1/2024$12.00 → $9.00Neutral → Underweight
    JP Morgan
    10/1/2024$24.00 → $12.00Buy → Hold
    Truist
    More analyst ratings

    $IGMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRINCIPAL ACCOUNTING OFFICER Weber Steven sold $2,090 worth of shares (1,865 units at $1.12), decreasing direct ownership by 6% to 27,016 units (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      5/16/25 4:05:57 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lee Michael Stewart was granted 828 shares (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      4/2/25 9:01:06 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Redmile Group, Llc was granted 828 shares (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      4/2/25 9:00:16 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • IGM Biosciences downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded IGM Biosciences from Outperform to Market Perform and set a new price target of $2.00 from $21.00 previously

      1/10/25 8:15:47 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded IGM Biosciences from Equal-Weight to Underweight and set a new price target of $2.00 from $12.00 previously

      1/10/25 8:15:47 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences downgraded by Stifel with a new price target

      Stifel downgraded IGM Biosciences from Buy to Hold and set a new price target of $2.50 from $27.00 previously

      1/10/25 8:15:16 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

      – Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory diseases, today announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases.    "Interim data

      1/9/25 1:00:00 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

      – Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended September 30, 2024 and provided an update on recent developments. "The third quarter was transformative for IGM, punct

      11/8/24 7:00:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences to Present at Three Upcoming Investor Conferences

      MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences: Guggenheim Healthcare Innovation Conference on Monday, November 11 at 11:30 a.m. EST in BostonStifel Healthcare Conference on Tuesday, November 19 at 12:40 p.m. EST in New YorkJefferies London Healthcare Conference on Thursday, November 21 at 8:00 a.m. GMT/ 3:00 a.m. EST in London A live webcast of the events will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at http

      11/4/24 7:00:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Baker Bros. Advisors Lp bought $3,425,569 worth of shares (395,317 units at $8.67) (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      3/28/24 7:04:05 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baker Bros. Advisors Lp bought $3,431,464 worth of shares (532,693 units at $6.44) (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      12/15/23 5:32:35 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    SEC Filings

    See more
    • IGM Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - IGM Biosciences, Inc. (0001496323) (Filer)

      6/11/25 5:07:57 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - IGM Biosciences, Inc. (0001496323) (Filer)

      5/29/25 4:05:25 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by IGM Biosciences Inc.

      10-Q - IGM Biosciences, Inc. (0001496323) (Filer)

      5/13/25 4:05:32 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Financials

    Live finance-specific insights

    See more
    • IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

      – Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended September 30, 2024 and provided an update on recent developments. "The third quarter was transformative for IGM, punct

      11/8/24 7:00:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

      – Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler, M.D., appointed as Chief Executive Officer and to Board of Directors – – Cash runway extended into 2027 – – Company to hold conference call and webcast today at 4:30 p.m. EDT – MOUNTAIN VIEW, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in the development

      9/30/24 4:01:00 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

      – Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose cohort cleared in imvotamab rheumatoid arthritis clinical trial – – First dose cohort cleared in imvotamab systemic lupus erythematosus clinical trial – MOUNTAIN VIEW, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) --  IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended June 30, 2024 and provided an update on recent developments. "We continue to make significant progress in the clinical

      8/14/24 7:00:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care